Login / Signup

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.

James R SeiboldToby M MaherKristin B HighlandShervin AssassiArata AzumaLaura Kathleen HummersUlrich CostabelUte von WangenheimVeronika KohlbrennerMartina GahlemannMargarida AlvesOliver Distlernull null
Published in: Annals of the rheumatic diseases (2020)
The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis. Dose adjustment is important to minimise the impact of adverse events and help patients remain on therapy.
Keyphrases